KUALA LUMPUR: An executive order signed by US President Donald Trump is not seen to have much impact on the Malaysian pharmaceutical sector, though there could be increased scrutiny on drug costs and the local supply chain.
In his signed order, Trump had directed drugmakers in the United States to lower the prices of their medicines in the country to align with what other countries pay – by some 30% to 80% – noting prices in some countries were lower than what was sold in the United States.
